Form 4: Lexeo Therapeutics CEO Richard Townsend Sells Shares to Cover Tax Obligations
SEC Form 4
Lexeo Therapeutics CEO Richard Nolan Townsend sold 1,074 shares of common stock on May 16, 2025, to cover tax obligations related to the release of restricted stock units.
Summary
- Richard Nolan Townsend, CEO of Lexeo Therapeutics, sold 1,074 shares of common stock on May 16, 2025.
- The sale was executed at a price of $2.774 per share.
- The transaction was conducted to cover tax obligations arising from the release of restricted stock units (RSUs).
- Following the transaction, Townsend directly owns 221,173 shares, which includes 133,827 RSUs.
Sentiment
Score: 6
Explanation: The document describes a routine transaction (sale of shares to cover tax obligations). It's neutral in nature and doesn't indicate any significant positive or negative sentiment.
Industry Context
This is a routine transaction for executives to cover tax obligations related to stock-based compensation. It is common for executives to sell a portion of their shares to cover these obligations.
Stakeholder Impact
- The sale of shares by the CEO may have a minor impact on shareholders, but it is unlikely to be significant given the relatively small number of shares sold.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of the stock sale transaction. |
| 05/20/2025 | Date of signature on the Form 4 filing. |
Keywords
Lexeo Therapeutics, Richard Nolan Townsend, LXEO, stock sale, Form 4, CEO, restricted stock units, tax obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.